Resultados da pesquisa - Mario Campone

Refinar resultados
  1. 1
    Vinflunine: A New Microtubule Inhibitor Agent

    Vinflunine: A New Microtubule Inhibitor Agent Por Jaafar Bennouna, Jean‐Pierre Delord, Mario Campone, Laurent Nguyen

    Publicado em 2008
    Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  2. 2
    Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer

    Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer Por Pauline du Rusquec, Cyriac Blonz, Jean‐Sébastien Frénel, Mario Campone

    Publicado em 2020
    Obter o texto integral Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  3. 3
    <p>Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data</p>

    <p>Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data</p> Por Pauline du Rusquec, Ombline de Calbiac, Marie Robert, Mario Campone, Jean‐Sébastien Frénel

    Publicado em 2019
    Obter o texto integral Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  4. 4
    YM155 potently triggers cell death in breast cancer cells through an autophagy-NF-kB network

    YM155 potently triggers cell death in breast cancer cells through an autophagy-NF-kB network Por Éloïse Véquaud, Céline Séveno, Delphine Loussouarn, Lucie Engelhart, Mario Campone, Philippe Juin, Sophie Barillé‐Nion

    Publicado em 2015
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  5. 5
    bc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analyses

    bc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analyses Por P. Jezequel, Jean‐Sébastien Frenel, L. Campion, Catherine Guérin‐Charbonnel, Wilfried Gouraud, Gabriel Ricolleau, Mario Campone

    Publicado em 2013
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  6. 6
    bc-GenExMiner 4.5: new mining module computes breast cancer differential gene expression analyses

    bc-GenExMiner 4.5: new mining module computes breast cancer differential gene expression analyses Por Pascal Jézéquel, Wilfried Gouraud, Fadoua Ben Azzouz, Catherine Guérin‐Charbonnel, Philippe Juin, Hamza Lasla, Mario Campone

    Publicado em 2021
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  7. 7
    Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer

    Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer Por C. Domergue, E. Martin, Camille Lemarié, Pascal Jézéquel, Jean‐Sébastien Frénel, Paule Augereau, Mario Campone, Anne Patsouris

    Publicado em 2022
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  8. 8
    miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells

    miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells Por Sonia G. Das, Mathilde Romagnoli, Nora D. Mineva, Sophie Barillé‐Nion, Pascal Jézéquel, Mario Campone, Gail E. Sonenshein

    Publicado em 2016
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  9. 9
    Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors

    Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors Por Frédérique Nguyen, L. Peña, Catherine Ibisch, Delphine Loussouarn, Adelina Gama, Natascha Rieder, Anton Belousov, Mario Campone, Jérôme Abadie

    Publicado em 2017
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  10. 10
    Validation of UBE2C protein as a prognostic marker in node-positive breast cancer

    Validation of UBE2C protein as a prognostic marker in node-positive breast cancer Por Delphine Loussouarn, L. Campion, F. Leclair, Mario Campone, Catherine Guérin‐Charbonnel, Gabriel Ricolleau, Wilfried Gouraud, Régis Bataille, Pascal Jézéquel

    Publicado em 2009
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  11. 11
    Ribociclib + letrozole vs placebo + letrozole in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC) and a high disease burden

    Ribociclib + letrozole vs placebo + letrozole in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC) and a high disease bu... Por Sunil Verma, Miguel Gil‐Gil, Roberto Hegg, Paul Wheatley‐Price, Joseph Kattan, Hugues Bourgeois, Santosh Sutradhar, Marshall G. Miller, Mario Campone

    Publicado em 2017
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  12. 12
    Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy

    Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy Por Paule Augereau, Anne Patsouris, Emmanuelle Bourbouloux, Carole Gourmelon, Sophie Abadie Lacourtoisie, Dominique Berton Rigaud, P Soulié, Jean‐Sébastien Frénel, Mario Campone

    Publicado em 2017
    Obter o texto integral Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  13. 13
    Canine invasive mammary carcinomas as models of human breast cancer. Part 2: immunophenotypes and prognostic significance

    Canine invasive mammary carcinomas as models of human breast cancer. Part 2: immunophenotypes and prognostic significance Por Jérôme Abadie, Frédérique Nguyen, Delphine Loussouarn, L. Peña, Adelina Gama, Natascha Rieder, Anton Belousov, Ingrid Bemelmans, Laëtitia Jaillardon, Catherine Ibisch, Mario Campone

    Publicado em 2017
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  14. 14
    Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response

    Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response Por Pascal Jézéquel, Delphine Loussouarn, Catherine Guérin‐Charbonnel, L. Campion, Antoine Vanier, Wilfried Gouraud, Hamza Lasla, Catherine Guette, Isabelle Valo, Véronique Verrièle, Mario Campone

    Publicado em 2015
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  15. 15
    Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab

    Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab Por Fabrice André, Mario Campone, Ruth O’Regan, C. Manlius, Cristian Massacesi, Sahmoud Tarek, Pabak Mukhopadhyay, Jean‐Charles Soria, Michael Naughton, Sara A. Hurvitz

    Publicado em 2010
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  16. 16
    Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2

    Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribocic... Por Sunil Verma, Joyce O’Shaughnessy, Howard A. Burris, Mario Campone, Emilio Alba, David Chandiwana, Anand A. Dalal, Santosh Sutradhar, Mauricio Monaco, Wolfgang Janni

    Publicado em 2018
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  17. 17
    Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study

    Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study Por François‐Clément Bidard, David Hajage, Thomas Bachelot, Suzette Delaloge, Étienne Brain, Mario Campone, Paul Cottu, Philippe Beuzeboc, Emilie Rolland, Claire Mathiot, Jean‐Yves Pierga

    Publicado em 2012
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  18. 18
    High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients

    High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic... Por Jean‐Yves Pierga, David Hajage, Thomas Bachelot, Suzette Delaloge, Étienne Brain, Mario Campone, Véronique Dièras, Emilie Rolland, L. Mignot, Claire Mathiot, François‐Clément Bidard

    Publicado em 2011
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  19. 19
    Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer

    Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer Por Sjoerd T. Ligthart, François‐Clément Bidard, Charles Decraene, Thomas Bachelot, Suzette Delaloge, Étienne Brain, Mario Campone, Patrice Viens, Jean‐Yves Pierga, Leon W.M.M. Terstappen

    Publicado em 2012
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  20. 20
    Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study

    Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study Por Suzette Delaloge, R. Wolp-Diniz, Tomasz Byrski, Joanne L. Blum, Anthony Gonçalvès, Mario Campone, Pilar Lardelli, Carmen Kahatt, Antonio Nieto, Martín Cullell-Young, Jan Lubiński

    Publicado em 2014
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:

Ferramentas de pesquisa: